Alnylam to Sell $125M in Stock

Premium

Alnylam Pharmaceuticals this week announced that it will raise $125 million through the public sale of common stock.

The move comes as Alnylam stock is riding at around $19.90 a share, near a 52-week high of $21.38. It also follows the company's recent litigation settlement with one-time partner Tekmira Pharmaceuticals, which called for Alnylam to pay out $65 million to end the dispute (GSN 11/15/2012).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.